ArticleClinicoEconomics and outcomes research : CEOR2011

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.

Hamid Reza Rasekh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.